Skip to main content
SpringerLink
Log in
Book cover

Gastric Cancer pp 415–424Cite as

New Systemic Chemotherapy

  • Chapter

  • 147 Accesses

Abstract

While the annual incidence of gastric cancer has been steadily declining in many Western countries, it remains a very frequent tumor in Japan and in most of Europe.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cunningham D (1988) Gastric cancer—the recognition of a chemosensitive tumour. Br J Cancer 58: 695–699

    Article  PubMed  CAS  Google Scholar 

  2. Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke H, Meyer J, Bünte H (1988) Chemotherapy of gastric cancer. Cancer Treat Rev 15: 257–277

    Article  PubMed  CAS  Google Scholar 

  3. Preusser P, Wilke H, Achterrath W, Lenaz L, Stahl M, Casper J, Meyer HJ, Meyer J, Blum M, Schmoll HJ (1990) Phase II study of carboplatin in untreated inoperable advanced stomach cancer. Eur J Cancer 26: 1108–1109

    Article  PubMed  CAS  Google Scholar 

  4. Beer M, Cavalli F, Kaye SB, Lev LM, Clavel M, Smyth J, van Glabbeke M, Renard J, Pinedo HM (1987) A phase II study of carboplatin in advanced or metastatic stomach cancer. Eur J Cancer Clin Oncol 23: 1365–1367

    Article  Google Scholar 

  5. Kelsen D, Atig O, Saltz L, Toomasi F, Trochanowski B, Niedzwiecki D (1991) FAMTX [fluorouracil (F), methotrexate (MTX), adriamycin (A)] is as effective and less toxic than EAP [etoposide (E), A, cisplatin (P)]: A random-assigned trial in gastric cancer (GC) (abstract). Proc Am Soc Clin Oncol 10: 137

    Google Scholar 

  6. Wils JA, Klein HO, Wagener DJT, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, Duesz N (1991) Sequential high-dose methotrexate and fluorouracil combined with doxorubicin— a step ahead in the treatment of advanced gastric cancer. A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9: 872–831

    Google Scholar 

  7. Kim NK, Park YS, Suh CI, Kan WK, Kim HT, Heo DS, Bang YJ (1991) Phase III randomized comparison of 5-FU vs FAM (5-FU/ADRIA/MMC) vs FP (5-FU/ Cisplatin) in patients with advanced gastric carcinoma (AGC) (abstract). Proc Am Soc Clin Oncol 10: 144

    Google Scholar 

  8. Klein HO, Wickramanayake D, Farrokh GH (1986) 5-Fluorouracil (5-FU), Adriamycin (ADM) and methotrexate (MTX)—a combination protocol (FAMTX) for treatment of metastasized stomach cancer (abstract). Proc Am Soc Clin Oncol 5: 84

    Google Scholar 

  9. Herrmann R, Fritze D, Queißer W, Flechtner H, Ho AD, Schlag P, König H (1984) Chemotherapie des Magenkarzinoms. DMW 109: 1704

    Google Scholar 

  10. Wils J, Bleiberg H, Blijham G (1986) An EORTC gastrointestinal group evaluation of the combination of sequential methotrexate (MTX) and 5-fluorouracil (F), combined with Adriamycin (A) (FAMTX) in advanced measurable gastric cancer. J Clin Oncol 4: 1799–1803

    PubMed  CAS  Google Scholar 

  11. Taguchi T, Ohta J, Orino M, Oshiba S, Yamada S, Okazima K, Ohtani T, Hurukawa H, Iwanaga T, Numata N (1990) Combination chemotherapy with etoposide, ADM, CDDP (EAP) for advanced gastric cancer. Gan To Kagaku Ryoho 17 (11): 2191–2196

    PubMed  CAS  Google Scholar 

  12. Tokunaga A, Onda M, Mizutani T, Miyamoto M, Nomura T, Hayashi H, Kiyama T, Umehara M, Nishi K, Andoh T (1989) Combination chemotherapy with etoposide, adriamycin and cisplatin in advanced primary and recurrent gastric cancer. Gan To Kagaku Ryoho 16 (12): 3713–3718

    PubMed  CAS  Google Scholar 

  13. Katz A, Gansl RC, Simon SD, Gama-Rodrigues J, Waitzberg D, Bresciani CJ, Pinotti HW (1991) Phase II trial of etoposide (V), adriamycin (A), and cisplatinum (P) in patients with metastatic gastric cancer. Am J Clin Oncol 14 (4): 357–358

    Article  PubMed  CAS  Google Scholar 

  14. Kim SY, Song MH, Park CS, Lee HY, Kim YK, Lee BH, An BJ (1989) Etoposide, adriamycin, and cisplatin (EAP) combination chemotherapy for advanced gastric cancer (abstract). Blut 59: 257

    Google Scholar 

  15. Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, Lenaz L, Meyer J, Siewert JR, Geerlings H, Köhne-Wömpner CH, Harstrick A, Schmoll HJ (1990) New developments in the treatment of gastric cancer Semin Oncol 17 [Suppl 2]: 61–70

    CAS  Google Scholar 

  16. Lerner A, Steele GD, Meyer RJ (1990) Etoposide, doxorubicin, cisplatin (EAP) chemotherapy for advanced gastric adenocarcinoma: Results of a phase II trial (abstract). Proc Am Soc Clin Oncol 9: 103

    Google Scholar 

  17. Raeth U, Flechtner H, Selbach J, Harjung H, Manegold C, Kabelitz K, Trux FA, Edler L, Schlag P, Queißer W (1990) Etoposide, adriamycin, and cisplatinum (EAP) combination chemotherapy for advanced gastric cancer. Onkologie 13: 194–197

    Article  Google Scholar 

  18. Villar-Grimalt A, Candel MT, Garcia J, Bernacer B, Jimeno J (1991) Combination of etoposide, adriamycin and cisplatin (EAP) in gastric cancer: Association with severe toxicity. Ann Oncol 2: 310–311

    PubMed  CAS  Google Scholar 

  19. Haim N, Robinson E (1991) Combination of etoposide, adriamycin and cisplatin (EAP) in gastric cancer: Association with severe toxicity. Ann Oncol 2: 311–312

    PubMed  CAS  Google Scholar 

  20. Bajetta E, Di Bartolomeo M, Buzzoni R, Lambiase A, Biganzoli I (1991) Doxorubicin, VP-16, CDDP (EAP) in advanced gastric cancer (AGC): A study by the Italian Trials in Medical Oncology (ITMO) Group (abstract). Eur J Cancer 91 [Suppl 2]: 79

    Google Scholar 

  21. Shimada Y, Yoshida S, Ohtsu A, Saito D, Miyamoto K, Yoshino M, Fujii T, Tajiri H, Yamaguchi H, Yoshino M, Yoshida T, Yishimori M, Ohkura H, Okazaki N (1990) A phase II study of combination chemotherapy with etoposide, adriamycin and cisplatin (EAP) for advanced gastric cancer in Japan (abstract). J Cancer Res Clin Oncol 116 [Suppl]: 673

    Google Scholar 

  22. Stahl M, Wilke H, Preusser P, Fink U, Achterrath W, Schöber C, Köhne-Wömpner CH, Harstrick A, Meyer HJ, Meyer J, Lenaz L, Schmoll HJ (1991) Etoposide, leukovorin and 5-fluorouracil (ELF) in advanced gastric carcinoma—final results of a phase-II study in elderly patients or patients with cardial risk. Onkologie 14: 314–318

    Article  Google Scholar 

  23. Wilke H, Preusser P, Stahl M, Harstrick A, Meyer HJ, Achterrath W, Schmoll HJ, Seeber S (1991) Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. Cancer Chemother Pharmacol 29: 83–84

    Article  PubMed  CAS  Google Scholar 

  24. Mahjoubi M, Rougier P, Oliviera J, Tigaud JM, Bognel C, Lasser P, Droz JP (1990) Phase II trial of combined 5-FU + CDDP in gastric cancer (GC) (abstract). J Cancer Res Clin Oncol (Suppl, part 1 ) 116: 677

    Google Scholar 

  25. Yoshida S, Shimada Y, Saito D, Ohtsu A, Shirao K, Sugano K, Ohkura H, Yoshino M, Soshimori M (1991) Phase II trial of 5-fluorouracil (FU) and cisplatin (CDDP) in metastatic cancer, as second-line chemotherapy (abstract). Proc Am Soc Clin Oncol 10: 160

    Google Scholar 

  26. Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LMG, Palacio I, Esteban E, Gracia JM, Buesa JM, Fernandez OA, Baron MG (1991) Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A phase II trial. Ann Oncol 2: 751–754

    PubMed  CAS  Google Scholar 

  27. Findlay M, Mansi JL, Ford HT, Nash AT, Cunningham D (1991) Epirubicin, cisplatin and 5-fluorouracil (ECF) is highly effective in advanced gastric cancer (abstract). Eur J Cancer [Suppl 2]: 71

    Google Scholar 

  28. Coombes RC, Schein PS, Chilvers CED, Wils J, Beretta G, Bliss JM, Rutten A, Amadori D, Cortes-Funs H, Villar-Grimalt A, McArdle C, Rauschecker HF, Boven E, Vassilopoulos P, Welvaart K, Pinto Ferreira E, Wiig J, Gisselbrecht C, Rougier P, Woods EMA (1990) A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. J Clin Oncol 8: 1362–1369

    PubMed  CAS  Google Scholar 

  29. Gastrointestinal Tumor Study Group (1982) Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 49: 1116–1122

    Google Scholar 

  30. Kim BS, Chung CH, Roh JK, Park YJ, Koh EH, Kim JH, Min JS, Lee KS, Lee KB, Youn JK (1991) A controlled trial of 5-FU, doxorubicin (FA) chemotherapy vs FA-polyadenylic, polyuridylic acid (poly-AU) chemoimmunotherapy for locally advanced gastric cancer after curative resection: An interim report (abstract). Proc Am Soc Clin Oncol 10: 134

    Google Scholar 

  31. Fujimoto S, Akao T, Ito B, Koshizuka I, Koyano K (1976) A study of survival in patients with stomach cancer treated by a combination of preoperative intra-arterial infusion thrapy and surgery. Cancer 37: 1648–1654

    Article  PubMed  CAS  Google Scholar 

  32. Nishioka B, Ouchi T, Watanabe S, Umehara M, Yamane E, Yahata K, Muto F, Kojima O, Nomiyama S, Sakita M, Fujita Y, Majima S (1982) Follow-up study of preoperative oral administration of an antineoplastic agent as an adjuvant chemotherapy in stomach cancer. Gan To Kagaku Ryoho 9: 1427–1430

    PubMed  CAS  Google Scholar 

  33. Jinnai D, Higashi H (1976) Extended radical operation with preoperative chemotherapy for gastric cancer. In: Hirayama T (ed) Cancer in Asia. University Park Press, Baltimore

    Google Scholar 

  34. Stephens FO (1988) Management of gastric cancer with regional chemotherapy proceding gastrectomy-5-year survival results. Reg Cancer Treat 1: 80–82

    Google Scholar 

  35. Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson, DE, Roh M, Hohn D (1991) Resectable gastric carcinoma—An evaluation of preoperative and postoperative chemotherapy. Cancer 68: 1501–1506

    Article  PubMed  CAS  Google Scholar 

  36. Leichman L, Silberman H, Leichman C, Laine L, Ramos H, Spears P, Jeffers S (1990) Neoadjuvant chemotherapy for gastric adenocarcinoma followed by postoperative intraperitoneal (IP) chemotherapy (abstract). Proc Am Soc Clin Oncol 9: 109

    Google Scholar 

  37. Iaffaioli RV, Frasci G, Facchini G, Tortoriello A, Persico G, Canove G, Bianco AR (1991) Neoadjuvant immunochemotherapy (FEP-IFN) in locally advanced gastric cancer (abstract). Preliminary data. Eur J Cancer [Suppl 2]: 77

    Google Scholar 

  38. Verschueren RJC, Willemse PHB, Sleijfer DTH, de Vries EGE, Mulder HH (1988) Combined chemotherapeutic-surgical approach of locally advanced gastric cancer (abstract). Proc Am Soc Clin Oncol 7: 93

    Google Scholar 

  39. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, Knipp H, Schmoll HJ (1989) Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7: 1318–1326

    PubMed  CAS  Google Scholar 

  40. Kuitunen T, Pyrhönen S (1991) A randomized phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with no treatment in nonresectable gastric cancer (abstract). Eur J Cancer [Suppl 2]: 80

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Allgemeine Chirurgie, Westfälische Wilhelms-Universität Münster, Jungeblodtplatz 1, 4400, Münster, Germany

    H. Wilke

Authors
  1. P. Preusser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Institute Hospital, 1-37-1 Kami-Ikebukuro, Toshima-ku, Tokyo, 170, Japan

    Mitsumasa Nishi M.D.

  2. National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104, Japan

    Heizaburo Ichikawa M.D.

  3. Department of Surgery, Cancer Institute Hospital, 1-37-1 Kami-Ikebukuro, Toshima-ku, Tokyo, 170, Japan

    Toshifusa Nakajima M.D.

  4. Gastric Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104, Japan

    Keiichi Maruyama M.D.

  5. Department of Pathology, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734, Japan

    Eiichi Tahara M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Japan

About this chapter

Cite this chapter

Preusser, P., Wilke, H. (1993). New Systemic Chemotherapy. In: Nishi, M., Ichikawa, H., Nakajima, T., Maruyama, K., Tahara, E. (eds) Gastric Cancer. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68328-5_31

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-68328-5_31

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-68330-8

  • Online ISBN: 978-4-431-68328-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation